CONTACT US

Skyepharma is a specialist CDMO

with particular expertise and capabilities in classic and complex oral solid dosage forms, being a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.

Fully integrated CDMO offering tailor-made solutions

We provide tailor-made solutions to our customers by positioning ourselves as a fully integrated CDMO offering a wide range of premium services.


Our experienced team of specialists works to optimize target product profile and drug development program from early formulation development, scale-up, manufacturing and packaging to regulatory support.

CDMO with a true D for Development:

Formulation development

We have extensive experience in solving complex formulation challenges. Our experts will advise you on the best solution to optimise drug delivery for the benefit to the patients. We could include our range of proprietary technologies to provide modified, pulse or timed release profiles  to solve technological challenges, to provide patient benefits and to offer additional proprietary protection to the product.

Prototyping

We perform rapid and flexible prototyping essays to early characterized powders leading to anticipate potential up scaling issues which lead to save time and money.


Our key differentiators regards our compression simulator (Styl’One Evolution) and low scale equipment which reproduce industrial processes such as wet granulation, compression including tabletting and roller compaction and coating.

Product manufacturing for clinical trial

Once formulation is validated, we use our cGMP facilities to supply product for clinical study. Regulatory support is provided to assist you during clinical phases.

Controlled release technologies

Oral Drug Delivery Technologies

Skyepharma controlled release expertise is the result of years as a leader in drug development and oral drug delivery technologies serving the global pharmaceutical industry. Since it was founded, Skyepharma has had a strong focus on oral drug delivery, solving the many challenges of delivering the right dose of a drug to the right part of the gastrointestinal system for absorption at the right time and at the appropriate rate to achieve the desired therapeutic effect.

Oral Patented Technologies

3 patented pharmaceutical technologies: Geomatrix®, Geoclock®,and Soctec®. These platforms allow us to build controlled release formulations to adapt to patient dosing schedules or adjust API intake. These proprietary technologies allow us to better manage side effects

Soctec®

Gastro retentive capsule

Brand new packaging lines - Serialization & aggregation: 

Since 2018, oral dosage CDMO Skyepharma radically updated and expanded its packaging capabilities, opening new packaging lines equipped for serialization and aggregation.  

WE ARE AVAILABLE FOR YOU

CONTACT US

Go to article: Home | EDS: Treating a medical zebraGo to article: Scandinavian Health LtdGo to article: EditorialGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Nolato Company Insight Go to article: NolatoGo to article: NewsGo to article: The pharma industry briefingGo to article: Subcuject Company Insight Go to article: SubcujectGo to article: Horizon 2020: a look back at flagship EU pharma projectsGo to article: SanofiGo to article: Sky high: should US drug prices fall in-line with the rest of the world?Go to article: Nipro PharmapackagingGo to article: Q&A: talking drug quality with Valisure, the first analytical pharmacyGo to article: NemeraGo to article: What does ‘ageing’ mean when it comes to drug development? Go to article: Swiss WorldCargoGo to article: Manufacturing medicines in space: how astronauts will make their own drugs Go to article: MimotopesGo to article: Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the deadGo to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Ehlers-Danlos syndrome: The zebra in the roomGo to article: KugelmeiersGo to article: Stop ignoring the two billion: pharma’s role in expanding access to medicineGo to article: SkyepharmaGo to article: IDMP: turning attention to patient benefitsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue